Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease

30 Sept 2024

Abstract excerpt

Objective: To investigate the effects of oral baricitinib on ocular surface disease (OSD) in patients with chronic graft-versus-host disease (cGVHD).Design: Prospective phase 1 to 2 single institution trial.Subjects: Eighteen patients with ocular graft-versus-host-disease (oGVHD) and systemic steroid-refractory cGVHD.Methods: Oral baricitinib (2 mg and 4 mg) was administered daily for up to 12 months in an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Corneal surgery and disorders
Share to Corneal Surgery and Treatments
Share to Ocular Surface and Contact Lens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39605875
DOI: 10.1016/j.xops.2024.100627

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host DiseasePMID 39605875Read ↗

Anti-inflammatory and anti-fibrotic effects of topical pan-JAK inhibitor in a chronic graft-versus- host disease model mouseSemantic proximity Read ↗

Recent advances in ocular graft-versus-host diseaseSemantic proximity Read ↗

Epithelial Mesenchymal Transition in Human Ocular Chronic Graft-Versus-Host DiseaseSemantic proximity Read ↗

Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host diseaseSemantic proximity Read ↗

Manifestation of Clinical Categories of Ocular Graft-versus-Host DiseaseSemantic proximity Read ↗

Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplantSemantic proximity Read ↗

Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal ModelSemantic proximity Read ↗

Ocular graft-versus-host disease (oGVHD): From A to ZSemantic proximity Read ↗

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of LifeSemantic proximity Read ↗

Prevalence of Dry Eye Syndrome After Allogeneic Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Ocular chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in an Italian referral centerSemantic proximity Read ↗

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.